HER 2 LOW-EXPRESSING BREAST CANCER
Clinical trials for HER 2 LOW-EXPRESSING BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 LOW-EXPRESSING BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 LOW-EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug dance: alternating two powerful meds may boost survival in Hard-to-Treat breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low metastatic triple-negative breast cancer live longer. About 260 participants will be randomly assigned to receive either the…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New study aims to improve how we measure drug response in breast cancer
Knowledge-focused Not yet recruitingThis study looks at whether a special type of PET scan can better detect if the drug trastuzumab deruxtecan (T-DXd) is working in people with HER2 low breast cancer that has spread. The goal is to identify non-responders earlier than standard CT scans, so they can avoid unnecessa…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:05 UTC